Allergan to buy back $10 billion of stock, Q1 earnings rise
May 11, 2016Research and Development, Sales and Marketing Allergan, Buy Back, Financial, Q1, earnings, results, revenue
Botox-maker Allergan (NYSE: AGN) said it plans to buy back as much as $10 billion in stock after completing the …
FDA expands Imbruvica label with new survival data
May 11, 2016Research and Development, Sales and Marketing AbbVie, FDA, Janssen, data, efficacy, expanded, imbruvica, label, late stage, phase III
The US Food and Drug Administration (FDA) has expanded the label of Imbruvica (ibrutinib) to include the data from recent …
Baxalta sues Chugai for haemophilia drug patent breach
May 11, 2016Research and Development Baxalta, Chugai, breach, court, haemophilia, infringe, infringement, patent, sue, suing
Baxalta has taken Chugai Pharmaceuticals to the Tokyo district court, claiming that the Japanese company has infringed upon its patent …
Incyte acquires Ariad’s European operations in $140 million deal
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ariad, Incyte, Operations, buy out, european, iclusig, leukaemia, out-license
Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will see the company acquire Ariad’s …
Cell Therapy signs £12.5 million licensing deal with Daiichi Sankyo for heart failure treatment
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Daiichi Sankyo, Deals, cell therapy, heart failure, licensing
UK-based Cell Therapy on Tuesday said it has signed a £12.5 million licensing deal with Japan’s Daiichi Sankyo (TYO: 4568) …
Medivation maybe mulling sale as bidding race heats up – Reports
May 10, 2016Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Cancer drugmaker Medivation (Nasdaq: MDVN) is evaluating a potential sale following the recent string of offers from big pharma firms, …
Takeda secures $38 million grant to develop affordable polio vaccine
May 10, 2016Manufacturing and Production, Research and Development Bill and Melinda Gates Foundation, Gates Foundation, Takeda, Vaccine, access, developing countries, grant, polio
Takeda Pharmaceuticals has received a $38 million grant from the Bill and Melinda Gates Foundation to develop a low-cost polio …
Scottish Medicines Consortium does not back Vertex’ cystic fibrosis drugs Orkambi, Kalydeco
May 10, 2016Manufacturing and Production, Research and Development Kalydeco, Orkambi, SMC, Vertex Pharma, cystic fibrosis, regulation
The Scottish Medicines Consortium did not back two cystic fibrosis therapies from Vertex Pharmaceutical (Nasdaq: VRTX). SMC did not recommend …
Second child cleared of leukaemia after Cellectis T-cell treatment
May 10, 2016Manufacturing and Production, Research and Development cellecits, childhood, children, designer cells, leukaemia, rare, t cells, t-cells
A targeted T-cell oncology therapy has successfully treated a second baby with aggressive leukaemia who has remained in remission after …
China evaluating investigations into pharma firms to take on drug pricing issue
May 9, 2016Business Services, Research and Development, Sales and Marketing China, France, G7, regulation
Lawmakers globally have acknowledged the concerns over unbridled drug costs as regulators stress the need for a more open debate …
UK pharma would benefit by remaining in EU, says ABPI
May 9, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Andrew Witty, EU, brexit, letter, observer, pascal soriot, remain, stay
With the EU vote approaching, the Association of the British Pharmaceutical Industry (ABPI) has brought together 93 signatories, including the …
Focus: Governments evaluate policies, reforms as drug pricing debate rages on
May 9, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
By Anjali Shukla Lawmakers in France are set to urge the leaders of G7 countries to put in place guidelines …
Chiesi set to acquire Medicine Co cardiovascular assets, say reports
May 9, 2016Sales and Marketing Chiesi, assets, cardiovascular, medicine co
Italian pharmaceutical company Chiesi are set to expand their global footprint as it nears an agreement to acquire Medicines Co’s …
Endo shares plunge almost 40% as company cuts FY outlook
May 9, 2016Sales and Marketing Endo International, earnings, outlook, revenue
Shares in Endo International (Nasdaq: ENDP) plunged to close down nearly 40% after the company cut its full-year earnings forecast …
BTG acquires promising oncology pipeline in Galil Medical takeover
May 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing $84 million, BTG, cryoablation, galil medical, oncology, takeover
BTG (LSE: BTG) has announced that is has agreed to acquire Galil Medical, a leading provider of cryoablation products for …
Phase III trial meets primary endpoint for Allergan’s fibroid treatment
May 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, fibroid, phase 3, phase III, ulipristal, ulipristal acetate, uterine fibroid
Allergan (NYSE: AGN), in collaboration with Gedeon Richter, has announced positive results from a pivotal Phase III trial evaluating the …
Weekly Movers: Bind Therapeutics, Sarepta, Idexx…
May 9, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Pfizer (NYSE: PFE) and Amgen (Nasdaq: AMGN) are rumoured to be considering a bid for Medivation just as French drug …
Clovis cuts staff by 35% after FDA knock back on lung cancer drug
May 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing FDA, Q1 results, clovis, failure, job cuts, job losses, rociletinib, workforce
Clovis Oncology (NASDAQ: CLVS) is set to cut up to 35% of its workforce following the US Food and Drug …
NICE recommends Sanofi, Amgen cholesterol drugs
May 6, 2016Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
KemPharm’s pain drug fails to get FDA committee backing for abuse-deterrent capabilities; shares plunge
May 6, 2016Medical Communications, Sales and Marketing
Shares in KemPharm (Nasdaq: KMPH) more than halved in pre-market trading after a US Food and Drug Administration advisory panel …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
